Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application

Gastroenterology Research and Practice

Volumn 2016, Issue , 2016, Pages

  Li, Kaichun ^a   Li, Jin ^a,b  

^a TONGJI UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APATINIB; BEVACIZUMAB; CETUXIMAB; EVEROLIMUS; FORETINIB; LAPATINIB; NIMOTUZUMAB; ONARTUZUMAB; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; REGORAFENIB; RILOTUMUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ADVANCED GASTRIC CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG EFFECT; HUMAN; MOLECULARLY TARGETED THERAPY; REVIEW; STOMACH CANCER; TREATMENT OUTCOME;

EID: 84962750799     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2016/4105615     Document Type: Review

References (49)

1. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, "Global cancer statistics, 2012, " CA-ACancer Journal for Clinicians, vol. 65, no. 2, pp. 87-108, 2015.
2. W. Chen, R. Zheng, H. Zeng, S. Zhang, and J. He, "Annual report on status of cancer in China, " Chinese Journal of Cancer Research, vol. 27, no. 1, pp. 2-12, 2011.
3. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, K. Oba, X. Paoletti et al. , "Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis, " European Journal of Cancer, vol. 49, no. 7, pp. 1565-1577, 2013.
4. J. D. Croxtall andK. McKeage, "Trastuzumab: inHER2-positive metastatic gastric cancer, " Drugs, vol. 70, no. 17, pp. 2259-2267, 2010.
5. Y. J. Bang, E. Van Cutsem, A. Feyereislova et al. , "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, " The Lancet, vol. 376, no. 9742, pp. 687-697, 2010.
6. L. Shen, J. M. Xu, F. Y. Feng et al. , "Trastuzumab in combination with chemotherapy versus chemotherapy alone for firstline treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport, " Zhonghua Zhong Liu Za Zhi, vol. 35, no. 4, pp. 295-300, 2013.
7. A. Sawaki, Y. Ohashi, Y. Omuro et al. , "Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study, " Gastric Cancer, vol. 15, no. 3, pp. 313-322, 2012.
8. M. H. Ryu, C. Yoo, J. G. Kimet al. , "Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer, " European Journal of Cancer, vol. 51, no. 4, pp. 482-488, 2015.
9. Y. Kurokawa, N. Sugimoto, H. Miwa et al. , "Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1), " British Journal of Cancer, vol. 110, no. 5, pp. 1163-1168, 2014.
10. Z. A. Wainberg, A. Anghel, A. J. Desai et al. , "Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo, " Clinical Cancer Research, vol. 16, no. 5, pp. 1509-1519, 2010.
11. J. R. Hecht, Y. J. Bang, S. K. Qin et al. , "Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiC Trial, " Journal of Clinical Oncology, vol. 31, no. 18, abstract LBA4001, 2013, ASCO Annual Meeting Proceedings ( Post Meeting Edition).
12. T. Satoh, R.-H. Xu, H. C. Chung et al. , "Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-a randomized, phase III study, " Journal of Clinical Oncology, vol. 32, no. 19, pp. 2039-2049, 2014.
13. S. Lorenzen, J. R. Knorrenschild, G. Haag et al. , "Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplifiedmetastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie, " European Journal of Cancer, vol. 51, no. 5, pp. 569-576, 2015.
14. J. Park do, N. J. Thomas, C. Yoon, and S. S. Yoon, "Vascular endothelial growth factor a inhibition in gastric cancer, " Gastric Cancer, vol. 18, no. 1, pp. 33-42, 2015.
15. A. Ohtsu, M. A. Shah, E. Van Cutsem et al. , "Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebocontrolled phase III study, " Journal of Clinical Oncology, vol. 29, no. 30, pp. 3968-3976, 2011.
16. L. Shen, J. Li, J. Xu et al. , "Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study), " Gastric Cancer, vol. 18, no. 1, pp. 168-176, 2015.
17. R. Geng and J. Li, "Apatinib for the treatment of gastric cancer, " Expert Opinion on Pharmacotherapy, vol. 16, no. 1, pp. 117-122, 2015.
18. J. Li, S. Qin, J. Xu et al. , "Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial, " Journal of Clinical Oncology, vol. 31, no. 26, pp. 3219-3225, 2013.
19. S. Qin, J. Li, J. Xu et al. , "Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial, " Journal of Clinical Oncology, vol. 32, no. 5, supplement, abstract 4003, 2014.
20. R. M. Poole and A. Vaidya, "Ramucirumab: first global approval, " Drugs, vol. 74, no. 9, pp. 1047-1058, 2014.
21. C. S. Fuchs, J. Tomasek, C. J. Yong et al. , "Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial, " The Lancet, vol. 383, no. 9911, pp. 31-39, 2014.
22. H. Wilke, K. Muro, E. Van Cutsem et al. , "Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial, " The Lancet Oncology, vol. 15, no. 11, pp. 1224-1235, 2014.
23. S. J. Casak, I. Fashoyin-Aje, S. J. Lemery et al. , "FDA approval summary: ramucirumab for gastric cancer, " Clinical Cancer Research, vol. 21, no. 15, pp. 3372-3376, 2015.
24. H. H. Yoon, J. C. Bendell, F. S. Braiteh et al. , "Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trial, " Journal of Clinical Oncology, vol. 32, article 5s, 2014.
25. Y. Ling, Y. Yang, N. Lu et al. , "Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blockingVEGF-induced tyrosine phosphorylation ofKDR/Flk-1 of endothelial cells, " Biochemical and Biophysical Research Communications, vol. 361, no. 1, pp. 79-84, 2007.
26. R. Xu, N. Ma, F. Wang et al. , "Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer, " OncoTargets and Therapy, vol. 6, pp. 925-929, 2013.
27. G. D. Demetri, P. Reichardt, Y.-K. Kang et al. , "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial, " The Lancet, vol. 381, no. 9863, pp. 295-302, 2013.
28. H. Huynh, R. Ong, and D. Zopf, "Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer, " Journal of Experimental & Clinical Cancer Research, vol. 34, no. 1, article 132, 2015.
29. N. Pavlakis, K. M. Sjoquist, E. Tsobanis et al. , "INTEGRATE: a randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC)-a study by the Australasian Gastrointestinal Trials Group (AGITG): final overall and subgroup results, " Annals of Oncology, vol. 26, supplement 4, Article ID iv119, 2015.
30. A. Okines, D. Cunningham, and I. Chau, "Targeting the humanEGFR family inesophagogastric cancer, " Nature Reviews Clinical Oncology, vol. 8, no. 8, pp. 492-503, 2011.
31. F. Lordick, Y.-K. Kang, H.-C. Chung et al. , "Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial, " The Lancet Oncology, vol. 14, no. 6, pp. 490-499, 2013.
32. T. Waddell, I. Chau, D. Cunningham et al. , "Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial, " The Lancet Oncology, vol. 14, no. 6, pp. 481-489, 2013.
33. N. C. vanGrieken, T. Aoyama, P. A. Chambers et al. , "KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and theWest: results from a large international multicentre study, " British Journal of Cancer, vol. 108, no. 7, pp. 1495-1501, 2013.
34. T. Crombet-Ramos, J. Rak, R. Pérez, and A. Viloria-Petit, "Antiproliferative, antiangiogenic and proapoptotic activity of H-R3: a humanized anti-EGFR antibody, " International Journal of Cancer, vol. 101, no. 6, pp. 567-575, 2002.
35. T. Crombet, L. Torres, E. Neninger et al. , "Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer, " Journal of Immunotherapy, vol. 26, no. 2, pp. 139-148, 2003.
36. T. Satoh, K. H. Lee, S. Y. Rha et al. , "Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer, " Gastric Cancer, vol. 18, no. 4, pp. 824-832, 2015.
37. F. Du, Z. Zheng, S. Shi et al. , "S-1 and cisplatin with or without nimotuzumab for patients with untreated unresectable or metastatic gastric cancer: a randomized, open-label phase 2 trial, " Medicine, vol. 94, no. 23, article e958, 2015.
38. S.-E. Al-Batran, M. Ducreux, and A. Ohtsu, "mTOR as a therapeutic target in patients with gastric cancer, " International Journal of Cancer, vol. 130, no. 3, pp. 491-496, 2012.
39. T. Doi, K. Muro, N. Boku et al. , "Multicenter phase II study of everolimus in patients with previously treatedmetastatic gastric cancer, " Journal of Clinical Oncology, vol. 28, no. 11, pp. 1904-1910, 2010.
40. A. Ohtsu, J. A. Ajani, Y.-X. Bai et al. , "Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study, " Journal of Clinical Oncology, vol. 31, no. 31, pp. 3935-3943, 2013.
41. R. Dabney, R. Devine, N. Sein, and B. George, "New agents in renal cell carcinoma, " Targeted Oncology, vol. 9, no. 3, pp. 183-193, 2014.
42. C. D. Hart, I. Migliaccio, L. Malorni, C. Guarducci, L. Biganzoli, andA. Di Leo, "Challenges in themanagement of advanced, ERpositive, HER2-negative breast cancer, " Nature Reviews Clinical Oncology, vol. 12, no. 9, pp. 541-552, 2015.
43. F. Lordick, "Targeting theHGF/MET pathway in gastric cancer, " The Lancet Oncology, vol. 15, no. 9, pp. 914-916, 2014.
44. T. Iveson, R. C. Donehower, I. Davidenko et al. , "Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study, " The Lancet Oncology, vol. 15, no. 9, pp. 1007-1018, 2014.
45. D. Cunningham, N. C. Tebbutt, I. Davidenko et al. , "Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study, " Journal of Clinical Oncology, vol. 33, supplement, abstract 4000, 2015.
46. M. A. Shah, Y.-J. Bang, F. Lordick et al. , "METGastric: a phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) andMET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC), " Journal of Clinical Oncology, vol. 33, supplement, abstract 4012, 2015.
47. Y. Kataoka, T. Mukohara, H. Tomioka et al. , "Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking interreceptor tyrosine kinase networks, " Investigational New Drugs, vol. 30, no. 4, pp. 1352-1360, 2012.
48. M. A. Shah, Z. A. Wainberg, D. V. T. Catenacci et al. , "Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer, " PLoS ONE, vol. 8, no. 3, Article ID e54014, 2013.
49. E. Elimova, R. Wadhwa, H. Shiozaki et al. , "Molecular biomarkers in gastric cancer, " Journal of the National Comprehensive Cancer Network, vol. 13, no. 4, pp. e19-e29, 2015.